INSR isoform split in TCGA stomach tumours, mean absolute error
Predict the INSR isoform percentages of 166 TCGA stomach adenocarcinomas from gene-level expression and score the mean absolute error in percentage points.
Overview
An explanatory profile has not yet been reviewed for this record.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
3 recorded evaluations, 3 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.
Results
Results are available, but no reviewed comparison panel is linked in this release.
All evaluations
3 evaluations · 3 results. Different protocols are not a single leaderboard.
Protocol: INSR isoform split in TCGA stomach tumours, mean absolute error · Dataset subset: TCGA stomach adenocarcinomas with INSR at least 10 TPM (166)
Sorted by MAE (mean absolute error of INSR isoform percentage, 166 TCGA stomach tumours) (lower is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.
| Tested configuration | MAE (mean absolute error of INSR isoform percentage, 166 TCGA stomach tumours) |
|---|---|
| Ladon, pretrained encoder, isoform percentages imputed from gene-level countsEvaluation | 4.9% (best in column) |
| Cohort-trained isoform ridge baseline (Ladon report)Evaluation | 6.6% |
| Cohort mean isoform splitEvaluation | 12.2% |
All 3 result rows with coverage, uncertainty and sources
Filter evaluations
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Method: Cohort mean isoform split | Protocol: INSR isoform split in TCGA stomach tumours, mean absolute error Dataset subset: TCGA stomach adenocarcinomas with INSR at least 10 TPM (166) | 12.2% MAE (mean absolute error of INSR isoform percentage, 166 TCGA stomach tumours) percent · lower Uncertainty: Not reported by the source: The caption says intervals are given, but none is printed for MAE. Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcecohort mean, INSR isoform split in 166 stomach tumours, MAE ladon-20261115-protocol-insr-stomach-mae Aggregation: Not reported Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 11 (page 24) readout 'MAE, points', 'cohort mean' |
| Method: Cohort-trained isoform ridge baseline (Ladon report) | Protocol: INSR isoform split in TCGA stomach tumours, mean absolute error Dataset subset: TCGA stomach adenocarcinomas with INSR at least 10 TPM (166) | 6.6% MAE (mean absolute error of INSR isoform percentage, 166 TCGA stomach tumours) percent · lower Uncertainty: Not reported by the source: The caption says intervals are given, but none is printed for MAE. Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcecohort-trained baseline, INSR isoform split in 166 stomach tumours, MAE ladon-20261115-protocol-insr-stomach-mae Aggregation: Not reported Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 11 (page 24) readout 'MAE, points', 'cohort-trained baseline' |
| Configuration: Ladon, pretrained encoder, isoform percentages imputed from gene-level counts | Protocol: INSR isoform split in TCGA stomach tumours, mean absolute error Dataset subset: TCGA stomach adenocarcinomas with INSR at least 10 TPM (166) | 4.9% MAE (mean absolute error of INSR isoform percentage, 166 TCGA stomach tumours) percent · lower Uncertainty: Not reported by the source: The caption says intervals are given, but none is printed for MAE. Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceLadon, INSR isoform split in 166 stomach tumours, MAE ladon-20261115-protocol-insr-stomach-mae Aggregation: Not reported Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 11 (page 24) readout 'MAE, points', 'Ladon' |
Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.
Methods and evaluation design
Procedure, tasks and evaluated configurations
Recorded evaluations
Each evaluation records what was tested and under which conditions.
Baseline coverage
Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.
0 of 2 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.
No execution recipe linked to this protocol. Recipe availability does not establish a completed evaluation.
- Author-reported evaluations
- 3
Literature evidence is not a Rewire measurement. Executed but unpublished runs and private review status are not included.
Null control
Proposed control: requires review
Select a task-valid null control after reviewing inputs and metric
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Conventional reference
Proposed control: requires review
Select an upstream conventional reference after reviewing the full protocol
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)
Coverage is derived from release 2026-11-21-c8bea25e5abb. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.
Run instructions
No runnable recipe has been reviewed for this protocol. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
0 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|
No evidence rows match these filters. Choose another scope or clear the search.
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
1 source record and release history
- Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Original source · Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Technical metadata and record identifiers
Technical metadata for this record is tracked under stable ID ladon-20261115-protocol-insr-stomach-mae.
Source locator: Figure 11 (page 24) readout 'MAE, points'
Related records
- evaluates task: Isoform usage recovery from gene-level expression
- uses data: TCGA stomach adenocarcinomas with INSR at least 10 TPM (166)
- used in: TCGA stomach adenocarcinomas with INSR at least 10 TPM (166)
- assessment: cohort mean, INSR isoform split in 166 stomach tumours, MAE
- assessment: cohort-trained baseline, INSR isoform split in 166 stomach tumours, MAE
- assessment: Ladon, INSR isoform split in 166 stomach tumours, MAE